Study on Drug Safety of Rosiglitazone and Pioglitazone in France
Author Information
Author(s): Berthet Stephanie, Olivier Pascale, Montastruc Jean-Louis, Lapeyre-Mestre Maryse
Primary Institution: Université de Toulouse
Hypothesis
What is the profile of adverse drug reactions related to thiazolidinediones (TZDs) in type 2 diabetic patients?
Conclusion
Thiazolidinediones exposure is associated with an increased risk of edema and heart failure in patients with type 2 diabetes, but the risk of hepatic reactions and myocardial infarction is similar to other hypoglycemic agents.
Supporting Evidence
- Among 99,284 patients, 2.3% were type 2 diabetic patients with 7% exposed to TZDs.
- Edema and heart failure were significantly more frequent in TZD patients compared to non-exposed patients.
- The risk of hepatic reactions and myocardial infarction with TZDs was similar to other hypoglycemic agents.
Takeaway
This study found that some diabetes medications can cause swelling and heart problems, but they don't seem to cause liver issues or heart attacks more than other diabetes drugs.
Methodology
The study analyzed adverse drug reactions reported in the French PharmacoVigilance Database from 2002 to 2006 for type 2 diabetic patients.
Potential Biases
Underreporting may affect the validity of results, as serious reactions may not be reported.
Limitations
The study is limited by the nature of spontaneous reporting, which may lead to underreporting of adverse drug reactions.
Participant Demographics
The mean age of participants was 67 years, with a high frequency of comorbidities.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI for heart failure: (17.678 - 241.93), for edema: (13.50 - 46.63)
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website